Soley Therapeutics Presents Preclinical Data Demonstrating Selective Anti-Tumor Activity of STX-6398, a First-in-Class CKAP2 ...

A novel imaging method captures ultrafast events with unprecedented detail by combining laser encoding and AI reconstruction. Researchers have introduced a new imaging method that reveals far more ...

Three posters accepted at AACR 2026 highlighting SK Life Science Labs' targeted protein degradation pipeline -- Programs featured: selective p300 and PRMT5 degraders -- p300 degrader data demonstrate: ...

This manuscript presents a valuable analysis of how locomotion modulates the activity of different subtypes of cortical neurons in the mouse primary visual cortex, showing that locomotion more ...

XTX601 demonstrated protease-dependent, tumor-selective activation and potent anti-tumor activity in multiple preclinical models Consistent with ...

HIV-1 envelope glycoprotein (Env), a gp120–gp41 trimer, undergoes coordinated conformational changes that drive membrane fusion and allow immune evasion by transiently concealing ...

FB301 was safe and well tolerated in healthy female subjects, with all primary and secondary endpoints metClinically meaningful microbiome ...

Marks First In-Human Clinical Study Demonstrating the Value of Immuno-Pharmacodynamics in the Assessment of Radioligand Therapy -- Novigenix AI Liquid Biopsy Platform Identifies Immune Activation ...

As EPR programs expand across the U.S., brands face overlapping deadlines and evolving rules. This article breaks down what’s ...

Seragon Biosciences Inc. today announced the publication of comprehensive preclinical study results in the peer-reviewed journal Drug Design, Development and Therapy, demonstrating that its ...

Reju Stem Cells celebrates four years of growth, advancing regenerative medicine with a focus on transparency, patient ...

Detailed price information for Cue Biopharma Inc (CUE-Q) from The Globe and Mail including charting and trades.